Skip to main
VERU

Veru (VERU) Stock Forecast & Price Target

Veru (VERU) Analyst Ratings

Based on 2 analyst ratings
Buy
Strong Buy 50%
Buy 50%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Veru Inc. is positioned favorably within a rapidly growing market for obesity and weight loss medications, particularly as the global spending on obesity treatments has surged to over $30 billion by 2024, reflecting a significant increase from approximately $3 billion in 2020. The company’s clinical development of enobosarm and sabizabulin targets key areas in the treatment of cardiometabolic and inflammatory diseases, with promising clinical outcomes that could enhance weight reduction and preserve lean mass, vital for appealing to healthcare providers and patients alike. Additionally, given the momentum seen in drug development and market capitalization increases among competitors, Veru's focus on unmet therapeutic needs presents a compelling opportunity in an expanding market landscape.

Bears say

Veru Inc faces significant development risks with its clinical-stage drugs, enobosarm and sabizabulin, which may not achieve regulatory approval or market success, potentially leading to a decrease in future revenue growth. Furthermore, intense competition in the biopharmaceutical sector may result in lower-than-expected revenues and increased scrutiny from regulatory agencies regarding efficacy and safety, which could adversely affect the company's stock performance. Additionally, high turnover in key regulatory roles, like CEO and CMO, raises concerns about leadership stability and strategic direction, further contributing to a negative outlook for Veru's financial prospects.

Veru (VERU) has been analyzed by 2 analysts, with a consensus rating of Buy. 50% of analysts recommend a Strong Buy, 50% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Veru and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Veru (VERU) Forecast

Analysts have given Veru (VERU) a Buy based on their latest research and market trends.

According to 2 analysts, Veru (VERU) has a Buy consensus rating as of Jan 12, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $22.50, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $22.50, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Veru (VERU)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.